BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 17292473)

  • 1. Morphometric effects of long-term exposure to latanoprost.
    Cracknell KP; Grierson I; Hogg P
    Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies.
    Cracknell KP; Grierson I; Hogg P; Appleton P; Pfeiffer N
    Exp Eye Res; 2003 Dec; 77(6):721-30. PubMed ID: 14609560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iris morphology.
    Teus MA; Arranz-Marquez E
    Ophthalmology; 2008 Feb; 115(2):418-9; author reply 419-20. PubMed ID: 18243921
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of irises with a latanoprost-induced change in iris color.
    Arranz-Marquez E; Teus MA; Saornil MA; Mendez MC; Gil R
    Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monte Carlo simulation of latanoprost induced iris darkening.
    Cracknell KP; Farnell DJ; Grierson I
    Comput Methods Programs Biomed; 2007 Aug; 87(2):93-103. PubMed ID: 17576020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study).
    Pfeiffer N; Grierson I; Goldsmith H; Appleton P; Hochgesand D; Winkgen A
    Arch Ophthalmol; 2003 Jan; 121(1):23-31. PubMed ID: 12523881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
    Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
    Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.
    Albert DM; Gangnon RE; Grossniklaus HE; Green WR; Darjatmoko S; Kulkarni AD
    Arch Ophthalmol; 2008 May; 126(5):626-31. PubMed ID: 18474771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histology and fine structure of the iris and outflow system following latanoprost therapy.
    Grierson I; Pfeiffer N; Cracknell KP; Appleton P
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latanoprost and pigmentation.
    Grierson I; Jonsson M; Cracknell K
    Jpn J Ophthalmol; 2004; 48(6):602-12. PubMed ID: 15592791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanin in the trabecular meshwork is associated with age, POAG but not Latanoprost treatment. A masked morphometric study.
    Cracknell KP; Grierson I; Hogg P; Majekodunmi AA; Watson P; Marmion V
    Exp Eye Res; 2006 Jun; 82(6):986-93. PubMed ID: 16297910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation.
    Imesch PD; Wallow IH; Albert DM
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S117-23. PubMed ID: 9154287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
    Chou SY; Chou CK; Kuang TM; Hsu WM
    Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of melanin in human iridal and choroidal melanocytes from eyes with various colored irides.
    Wakamatsu K; Hu DN; McCormick SA; Ito S
    Pigment Cell Melanoma Res; 2008 Feb; 21(1):97-105. PubMed ID: 18353148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue.
    Lindquist NG; Larsson BS; Stjernschantz J
    Exp Eye Res; 1999 Oct; 69(4):431-6. PubMed ID: 10504276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latanoprost-induced iris color darkening: a case report with long-term follow-up.
    Camras CB; Neely DG; Weiss EL
    J Glaucoma; 2000 Feb; 9(1):95-8. PubMed ID: 10708238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
    Tsai JC; Sivak-Callcott JA; Haik BG; Zhang J; McLean IW
    J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro.
    Drago F; Marino A; La Manna C
    Exp Eye Res; 1999 Jan; 68(1):85-90. PubMed ID: 9986745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latanoprost-induced changes in the iris and trabeculum: an electron-microscopic morphological study.
    Yildirim N; Sahin A; Kara S; Baycu C
    Int Ophthalmol; 2010 Feb; 30(1):93-7. PubMed ID: 19139827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change.
    Grierson I; Lee WR; Albert DM
    Arch Ophthalmol; 1999 Mar; 117(3):394-6. PubMed ID: 10088822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.